Whether successfully translated in in vivo studies, our findings could set the basis for innovative therapies based on p75NTR targeting for counteracting or alleviating symptoms associated with dystrophin deficiency. This evidence concerns the gene NGFR and neuromuscular disease caused by qualitative or quantitative defects of dystrophin.